Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey.

Iung, Bernard; Delgado, Victoria; Rosenhek, Raphael; Price, Susanna; Prendergast, Bernard; Wendler, Olaf; De Bonis, Michele; Tribouilloy, Christophe; Evangelista, Arturo; Bogachev-Prokophiev, Alexander; Apor, Astrid; Ince, Hüseyin; Laroche, Cécile; Popescu, Bogdan A; Piérard, Luc; Haude, Michael; Hindricks, Gerhard; Ruschitzka, Frank; Windecker, Stephan; Bax, Jeroen J; ... (2019). Contemporary Presentation and Management of Valvular Heart Disease: The EURObservational Research Programme Valvular Heart Disease II Survey. Circulation, 140(14), pp. 1156-1169. American Heart Association 10.1161/CIRCULATIONAHA.119.041080

Text Contemporary Presentation and Management of Valvular Heart Disease The EURO.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (271kB) | Request a copy

Background: Valvular heart disease (VHD) is an important cause of mortality and morbidity and has been subject to important changes in management. The VHD II survey was designed by the EURObservational Research Programme of the European Society of Cardiology (ESC) to analyze actual management of VHD and compare practice with guidelines. Methods: Patients with severe native VHD or previous valvular intervention were enrolled prospectively across 28 countries over a 3-month period in 2017. Indications for intervention were considered concordant if the intervention was performed or scheduled in symptomatic patients, corresponding to Class I recommendations specified in the 2012 ESC and in the 2014 American Heart Association/American College of Cardiology VHD guidelines. Results: 7247 patients (4483 hospitalized, 2764 out-patients) were included in 222 centers. Median age was 71 years (interquartile range 62-80); 1917 patients (26.5%) were aged ≥80 years and 3416 were female (47.1%). Severe native VHD was present in 5219 patients (72.0%): aortic stenosis (AS) in 2152 patients (41.2% of native VHD), aortic regurgitation (AR) in 279 (5.3%), mitral stenosis (MS) in 234 (4.5%), mitral regurgitation (MR) in 1114 (21.3%, primary in 746 and secondary in 368) multiple left-sided VHD in 1297 (24.9%) and right-sided VHD in 143 (2.7%). 2028 patients (28.0%) had undergone previous valvular intervention. Intervention was performed in 37.0% and scheduled in 26.8% of patients with native VHD. The decision for intervention was concordant with Class I recommendations in symptomatic patients with severe single left-sided native VHD in 79.4% (95% confidence interval [CI] 77.1-81.6%) for AS, 77.6% (95% CI 69.9-84.0%) for AR, 68.5% (95% CI 60.8-75.4%) for MS, and 71.0% (95% CI 66.4-75.3%) for primary MR. Valvular interventions were performed in 2150 patients during the survey; of them, 47.8% of patients with single left-sided native VHD were in New York Heart Association class III or IV. Transcatheter procedures were performed in 38.7% of patients with AS and 16.7% of those with MR. Conclusions: Despite good concordance between Class I recommendations and practice in patients with aortic VHD, the suboptimal figure in mitral VHD and late referral for valvular interventions suggest the need to improve further guideline implementation.

Interest & Impact

Downloads

1 since deposited on 10 Feb 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item